21 results on '"Mou, Yong-gao"'
Search Results
2. Survival Benefit from Surgical Resection in Lung Cancer Patients with Brain Metastases: a Single-Center, Propensity-Matched Analysis Cohort Study
- Author
-
Wang, Zhen-ning, Jiang, Xiao-bing, Lu, Jie, Guo, Xiao-yu, He, Zhen-qiang, Duan, Hao, Liang, Lun, Cui, Run, Hu, Hong-rong, Zhang, Xiang-heng, Zhong, Sheng, Li, Chang, Yu, Cheng-wei, Guo, Cheng-cheng, and Mou, Yong-gao
- Published
- 2022
- Full Text
- View/download PDF
3. Outcome and prognostic value of treatment for brain metastases and the primary tumor in patients with breast cancer brain metastases
- Author
-
Wang, Yang, Ji, Zhang, Lin, Fu Hua, Wang, Xiao-Hui, Wan-Ming, Hu, He, Zhen Qiang, Duan, Hao, Guo, Cheng-Cheng, Zhang, Xiang Heng, and Mou, Yong Gao
- Published
- 2018
- Full Text
- View/download PDF
4. Transforaminal Resection of Cervical Dumbbell Schwannomas in Patients with Additional Tumors
- Author
-
Zhang, Ji, Zhang, Xiang-heng, Wang, Zi-feng, Li, You-ping, Zhu, Zheng-quan, Sun, Ji-cheng, Chen, Zheng-he, Wu, Shao-yong, Sai, Ke, Wang, Jian, Mou, Yong-gao, and Chen, Zhong-ping
- Published
- 2017
- Full Text
- View/download PDF
5. Fluorescein sodium-guided biopsy or resection in primary central nervous system lymphomas with contrast-enhancing lesion in MRI
- Author
-
Lin, Fu-hua, Zhang, Xiang-heng, Zhang, Ji, He, Zhen-qiang, Duan, Hao, Ke, Chao, Sai, Ke, Jiang, Xiao-bing, AL-Nahari, Fuad, Xi, Shao-yan, and Mou, Yong-gao
- Published
- 2018
- Full Text
- View/download PDF
6. Low preoperative prognostic nutritional index predicts poor survival in patients with newly diagnosed high-grade gliomas
- Author
-
He, Zhen-Qiang, Ke, Chao, Al-Nahari, Fuad, Duan, Hao, Guo, Cheng-Cheng, Wang, Yang, Zhang, Xiang-Heng, Chen, Yin-Sheng, Liu, Zhi-Gang, Wang, Jian, Chen, Zhong-Ping, Jiang, Xiao-Bing, and Mou, Yong-Gao
- Published
- 2017
- Full Text
- View/download PDF
7. EphA2 is a functional entry receptor for HCMV infection of glioblastoma cells.
- Author
-
Dong, Xiao-Dong, Li, Yan, Li, Ying, Sun, Cong, Liu, Shang-Xin, Duan, Hao, Cui, Run, Zhong, Qian, Mou, Yong-Gao, Wen, Le, Yang, Bo, Zeng, Mu-Sheng, Luo, Min-Hua, and Zhang, Hua
- Subjects
GLIOBLASTOMA multiforme ,BRAIN tumors ,CONGENITAL disorders ,BENZOIC acid ,INFECTION - Abstract
Human cytomegalovirus (HCMV) infection is associated with human glioblastoma, the most common and aggressive primary brain tumor, but the underlying infection mechanism has not been fully demonstrated. Here, we show that EphA2 was upregulated in glioblastoma and correlated with the poor prognosis of the patients. EphA2 silencing inhibits, whereas overexpression promotes HCMV infection, establishing EphA2 as a crucial cell factor for HCMV infection of glioblastoma cells. Mechanistically, EphA2 binds to HCMV gH/gL complex to mediate membrane fusion. Importantly, the HCMV infection was inhibited by the treatment of inhibitor or antibody targeting EphA2 in glioblastoma cells. Furthermore, HCMV infection was also impaired in optimal glioblastoma organoids by EphA2 inhibitor. Taken together, we propose EphA2 as a crucial cell factor for HCMV infection in glioblastoma cells and a potential target for intervention. Author summary: Human cytomegalovirus (HCMV) belonged to β-human herpesvirus is a ubiquitous pathogen causing congenital infection and relating to morbidity and mortality in immunocompromised transplant patients. Moreover, HCMV has been demonstrated to promote the progression of glioblastoma, the most common and aggressive primary brain tumor. Many studies highlighted the inevitable relationship between HCMV and glioblastoma. But the underlying mechanism of HCMV infection of glioblastoma cells has not been fully demonstrated. Here we found that EphA2, a member of receptor tyrosine kinases (RTKs) family, played a crucial role in HCMV infection of glioblastoma cells. Our research suggests that EphA2 mediates the infection of HCMV by interacting with glycoproteins gH/gL/gO displaying on the surface of HCMV virion. We find that anti-EphA2 antibody and 2,5-dimethylpyrrolyl benzoic acid derivatives can block HCMV infection in glioblastoma cells, while 2,5-dimethylpyrrolyl benzoic acid derivatives can block HCMV infection in GBOs in a dose-dependent manner, indicating that the strategy of developing an anti-HCMV drug targeting EphA2 is feasible. Our findings may assist future studies striving for a better understanding of how HCMV infects glioblastoma cells and for potential new targets of innovative antiviral strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Lumber nerve root cavernous angioma
- Author
-
Sun, Shu-Xin, Zhang, Ji, Sun, Ji-Cheng, Chen, Zhi-Jie, Zhang, Xiang-Heng, Chen, Zheng-He, Huang, Jing-Xiu, Jiang, Yu, Mou, Yong-Gao, Chen, Zhong-Ping, and Sai, Ke
- Subjects
Health - Abstract
Byline: Shu-xin. Sun, Ji. Zhang, Ji-cheng. Sun, Zhi-jie. Chen, Xiang-heng. Zhang, Zheng-he. Chen, Jing-xiu. Huang, Yu. Jiang, Yong-gao. Mou, Zhong-ping. Chen, Ke. Sai Sir, A 51-year old man presented with [...]
- Published
- 2018
9. Brain metastases from colorectal carcinoma: a description of 60 cases in a single Chinese cancer center
- Author
-
Jiang, Xiao-Bing, Yang, Qun-Ying, Sai, Ke, Zhang, Xiang-Heng, Chen, Zhong-Ping, and Mou, Yong-Gao
- Published
- 2011
- Full Text
- View/download PDF
10. Surgical management of radiation-induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: Report of 14 cases
- Author
-
Mou, Yong-gao, Sai, Ke, Wang, Zhen-ning, Zhang, Xiang-heng, Lu, Yan-chun, Wei, Da-nian, Yang, Qun-ying, and Chen, Zhong-ping
- Published
- 2011
- Full Text
- View/download PDF
11. Brain metastases from hepatocellular carcinoma: clinical features and prognostic factors
- Author
-
Jiang Xiao-Bing, Ke Chao, Zhang Guan-Hua, Zhang Xiang-Heng, Sai Ke, Chen Zhong-Ping, and Mou Yong-Gao
- Subjects
Brain metastasis ,Hepatocellular carcinoma ,Prognosis ,Chinese ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Brain metastases (BM) from hepatocellular carcinoma (HCC) are extremely rare and are associated with a poor prognosis. The aim of this study was to define clinical outcome and prognostic determinants in patients with BM from HCC. Methods Between January 1994 and December 2009, all patients with HCC and BM treated in Sun Yat-sen University Cancer Center were retrospectively reviewed. Univariate and multivariate survival analyses were performed to identify possible prognostic factors. Results Forty-one patients were diagnosed with BM from HCC, an incidence of 0.47%. The median age at diagnosis of BM was 48.5 years. Thirty-three patients (80.5%) developed extracranial metastases at diagnosis of BM, and 30 patients (73.2%) had hepatitis B. Intracranial hemorrhage occurred in 19 patients (46.3%). BM were treated primarily either with whole brain radiation therapy (WBRT; 5 patients), stereotactic radiosurgery (SRS; 7 patients), or surgical resection (6 patients). The cause of death was systemic disease in 17 patients and neurological disease in 23. Patients in a high RPA (recursive partitioning analysis) class, treated with conservatively and without lung metastases, tended to die from neurological disease. Median survival after the diagnosis of BM was 3 months (95% confidence interval: 2.2-3.8 months). In multivariate analysis, the presence of extracranial metastases, a low RPA class and aggressive treatment, were positively associated with improved survival. Conclusions BM from HCC is rare and associated with an extremely poor prognosis. However, patients with a low RPA class may benefit from aggressive treatment. The clinical implication of extracranial metastases in HCC patients with BM needs further assessment.
- Published
- 2012
- Full Text
- View/download PDF
12. Intraparenchymal papillary meningioma of brainstem: case report and literature review
- Author
-
Jiang Xiao-Bing, Ke Chao, Han Zhi-An, Lin Shao-Hua, Mou Yong-Gao, Luo Rong-Zhen, Wu Shao-Xiong, and Chen Zhong-Ping
- Subjects
Meningioma ,Papillary ,Brain stem ,Intraparenchymal ,Cyst ,Surgery ,RD1-811 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Both intraparenchymal papillary meningioma and papillary meningioma with cyst formation of brainstem have never been reported. The authors present an extremely rare case of patient with intraparenchymal papillary meningioma of brainstem. A 23-year-old Chinese male presented with a 4-month history of progressive left upper limb and facial nerve palsy. Magnetic resonance imaging revealed a cystic-solid, heterogeneously enhancing mass in pons and right cerebral peduncle with no dural attachment. The tumor was totally removed via subtemporal approach. During surgery, the lesion was found to be completely intraparenchymal. Histological and immunohistochemical examinations were compatible with the diagnosis of papillary meningioma. The lesion recurred nine months after primary surgery, a second surgery followed by radiotherapy was performed. Till to now (nearly 2 years after the treatment), the patient is tumor free survival. Intraparenchymal meningioma of brainstem with cystic formation is very rare, however, it should be considered as a differential diagnosis of a brainstem neoplasm. The present case strongly recommended that postoperative radiotherapy was essential for the patients with papillary meningiomas.
- Published
- 2012
- Full Text
- View/download PDF
13. Immunogenomic Profiling Demonstrate AC003092.1 as an Immune-Related eRNA in Glioblastoma Multiforme.
- Author
-
Guo, Xiao-Yu, Zhong, Sheng, Wang, Zhen-Ning, Xie, Tian, Duan, Hao, Zhang, Jia-Yu, Zhang, Guan-Hua, Liang, Lun, Cui, Run, Hu, Hong-Rong, Lu, Jie, Wu, Yi, Dong, Jia-Jun, He, Zhen-Qiang, and Mou, Yong-Gao
- Subjects
GLIOBLASTOMA multiforme ,LINCRNA ,GLIOMAS ,LOG-rank test ,GENES ,FUNCTIONAL analysis - Abstract
Enhancer RNAs, a type of long non-coding RNAs (lncRNAs), play a critical role in the occurrence and development of glioma. RNA-seq data from 161 glioblastoma multiforme (GBM) samples were acquired from The Cancer Genome Atlas database. Then, 70 eRNAs were identified as prognosis-related genes, which had significant relations with overall survival (log-rank test, p < 0.05). AC003092.1 was demonstrated as an immune-related eRNA by functional enrichment analysis. We divided samples into two groups based on AC003092.1 expression: AC003092.1 High (AC003092.1_H) and AC003092.1 Low (AC003092.1_L) and systematically analyzed the influence of AC003092.1 on the immune microenvironment by single-sample gene-set enrichment analysis and CIBERSORTx. We quantified AC003092.1 and TFPI2 levels in 11 high-grade gliomas, 5 low-grade gliomas, and 7 GBM cell lines. Our study indicates that AC003092.1 is related to glioma-immunosuppressive microenvironment, and these results offer innovative sights into GBM immune therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Bone metastasis predicts poor prognosis of patients with brain metastases from colorectal carcinoma post aggressive treatment.
- Author
-
Duan, Hao, He, Zhen-Qiang, Guo, Cheng-Cheng, Li, Jue-Hui, Wang, Jian, Zhu, Zhe, Sai, Ke, Chen, Zhong-Ping, Jiang, Xiao-Bing, and Mou, Yong-Gao
- Subjects
BONE metastasis ,BRAIN metastasis ,COLON cancer prognosis ,COLON cancer treatment ,COLON cancer patients - Abstract
Purpose: The presence of brain metastasis (BM) in patients with colorectal cancer (CRC) is usually associated with terminal-stage illness; however, a subgroup of patients receiving aggressive treatment can have a satisfactory prognosis. This study was designed to investigate the profile of prognostic factors in CRC patients with BM treated aggressively. Patients and methods: CRC patients with BM were retrospectively reviewed. Survival analysis was performed to identify potential prognostic factors in the entire cohort of patients and a subgroup of patients treated aggressively. Aggressive treatments included surgical resection, radiotherapy, and/or chemotherapy. Overall survival was defined as the time between the diagnosis of BM and death or until the date of the last follow-up visit. Results: A total of 78 CRC patients were confirmed as having BM. Sixty-eight of them had extracranial metastases at the time of their BM diagnosis. The most common sites of extracranial metastases were lung (n=51, 65.4%), followed by liver (n=25, 32.1%) and bone (n=12, 15.4%). Fifty-one patients who were treated aggressively had significantly longer overall survival than those who accepted palliative care (14.1 months vs 2.0 months, P<0.0001). Multivariate analysis was applied, and the results showed that aggressive treatment (n=51), recursive partitioning analysis class I/II (hazard ratio [HR]=0.27, 95% CI: 0.12–0.6, P=0.001), and fewer BM (HR=0.4, 95% CI: 0.21–0.78, P=0.07) predicted longer survival. In contrast, the presence of bone metastasis, rather than lung or liver metastasis, at the time of diagnosis of BM (HR=2.38, 95% CI: 1.08–5.28, P=0.032) predicted a poor prognosis. Conclusions: Although the prognosis of CRC patients having BM is frequently very poor, those with good performance status and few brain lesions responded to aggressive treatment, while those with bone metastasis at the time of diagnosis of BM had relatively dismal survival rates, even when treated aggressively. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. High MMP-26 expression in glioma is correlated with poor clinical outcome of patients.
- Author
-
Guo, Jian-Gui, Guo, ChENg-ChENg, He, ZhEN-Qiang, Cai, Xiu-Yu, and Mou, Yong-Gao
- Subjects
MATRIX metalloproteinases ,GLIOMAS ,IMMUNOHISTOCHEMISTRY ,NEOVASCULARIZATION ,METASTASIS - Abstract
To date the management of glioma remains a great challenge in cancer therapy worldwide. The identification of novel diagnostic and therapeutic methods is required. Although there is data indicating that matrix metalloproteinase (MMP)-26 serves an important role in many human cancer types, its clinical significance in glioma remains uncertain. The present study aimed to evaluate MMP-26 expression in human astrocytic glioma specimens, and investigate its role and significance in the progression of astrocytic glioma. Immunohistochemistry was performed to assess MMP-26 expression in astrocytic glioma tissues. The levels of MMP-26 expression and its relevance to the clinicopathological features and prognostic factors in patients with astrocytic glioma patients were then investigated. The results demonstrated that MMP-26 expression was significantly assocaited with the World Health Organization grade (P<0.05). Additionally, it was identified that MMP-26 expression was an effective predictor of the overall survival of patients with astrocytic glioma (P<0.05). Analyses of univariate and multivariate Cox regression confirmed that MMP-26 expression was an independent factor for evaluating the prognosis of astrocytic glioma patients (P<0.05). The current results support that MMP-26 may be a novel indicator of diagnosis and an independent factor for evaluating prognosis in patients with glioma. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
16. Triptolide Synergistically Enhances Temozolomide-Induced Apoptosis and Potentiates Inhibition of NF-κB Signaling in Glioma Initiating Cells.
- Author
-
Sai, Ke, Li, Wen-Yu, Chen, Yin-Sheng, Wang, Jian, Guan, Su, Yang, Qun-Ying, Guo, Cheng-Cheng, Mou, Yong-Gao, Li, Wei-Ping, and Chen, Zhong-Ping
- Abstract
Glioblastoma multiforme (GBM) is a lethal solid cancer in adults. Temozolomide (TMZ) is a first-line chemotherapeutic agent but the efficacy is limited by intrinsic and acquired resistance in GBM. Triptolide (TPL), a derivative from traditional Chinese medicine, demonstrated anti-tumor activity. In this study, we explored the interaction of TPL and TMZ in glioma-initiating cells (GICs) and the potential mechanism. A GIC line (GIC-1) was successfully established. Cell viability of GIC-1 after treatment was measured using a CCK-8 assay. The interaction between TPL and TMZ was calculated from Chou-Talalay equations and isobologram. Self-renewal was evaluated with tumor sphere formation assay. Apoptosis was assessed with flow cytometry and western blot. Luciferase assay was employed to measure NF-κB transcriptional activity. The expression of NF-κB downstream genes, NF-κB nuclear translocalization and phoshorylation of IκBα and p65 were evaluated using western blot. We found that GIC-1 cells were resistant to TMZ, with the expected IC50 of 705.7 μmol/L. Co-treatment with TPL yielded a more than three-fold dose reduction of TMZ. TPL significantly increased the percentage of apoptotic cells and suppressed the tumor sphere formation when combined with TMZ. Phosphorylation of IκBα and p65 coupled with NF-κB nuclear translocalization were notably inhibited after a combined treatment. Co-incubation synergistically repressed NF-κB transcriptional activity and downstream gene expression. TPL sensitizes GICs to TMZ by synergistically enhancing apoptosis, which is likely resulting from the augmented repression of NF-κB signaling. TPL is therefore a potential chemosensitizer in the treatment of GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
17. Aspirin Increases Apolipoprotein-A-I-Mediated Cholesterol Efflux via Enhancing Expression of ATP-Binding Cassette Transporter A1.
- Author
-
Wang, Yu-Hua, Chen, Yan-Fang, Chen, Shao-Rui, Chen, Xi, Chen, Jian-Wen, Shen, Xiao-Yan, Mou, Yong-gao, and Liu, Pei-Qing
- Subjects
ASPIRIN ,APOLIPOPROTEINS ,CHOLESTEROL ,GENE expression ,PROTEIN binding ,ADENOSINE triphosphate ,REVERSE transcriptase polymerase chain reaction ,DRUG dosage ,PEROXISOMES ,ATHEROSCLEROSIS - Abstract
Background: The efflux of cellular cholesterol mediated by apolipoprotein (apo)A-I and ATP-binding cassette transporter A1 (ABCA1) is a major pathway of reverse cholesterol transport. We investigated the effect of aspirin on this process. Methods: The expression levels of ABCA1 in RAW264.7 cells were determined using reverse transcription polymerase chain reaction and Western blot analysis.
3 H-cholesterol efflux was measured by scintillation counting. Results: 0.5 mmol/l aspirin increased apoA-I-mediated cholesterol efflux and increased the expression of ABCA1. By increasing the dose of aspirin higher than 0.5 mmol/l, ABCA1 expression and function were significantly decreased. In cells transfected with a specific peroxisome proliferator-activated receptor (PPAR)-α small interfering RNA, the induction of ABCA1 expression and apoA-I-mediated3 H-cholesterol efflux by aspirin were substantially suppressed. Conclusions: The data demonstrate that low-dose aspirin increases ABCA1 expression via a PPAR-α-dependent mechanism and increases apoA-I-mediated cholesterol efflux. Copyright © 2010 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
18. Lumber nerve root cavernous angioma.
- Author
-
Shu-xin Sun, Ji Zhang, Ji-cheng Sun, Zhi-jie Chen, Xiang-heng Zhang, Zheng-he Chen, Jing-xiu Huang, Yu Jiang, Yong-gao Mou, Zhong-ping Chen, Ke Sai, Sun, Shu-Xin, Zhang, Ji, Sun, Ji-Cheng, Chen, Zhi-Jie, Zhang, Xiang-Heng, Chen, Zheng-He, Huang, Jing-Xiu, Jiang, Yu, and Mou, Yong-Gao
- Subjects
HIP joint abnormalities ,ANGIOMAS ,NEUROLOGY ,MOVEMENT disorders ,CAVERNOUS hemangioma - Abstract
The article presents a case study of a 51‑year old man, who was presented with a 5‑month history of acute pain bilaterally on the posterolateral aspect of his hip. It mentions that neurological examination revealed that the Lasegue sign was bilaterally positive, along with mild motor weakness. It mentions diagnosis of lumber nerve root cavernous angioma.
- Published
- 2018
- Full Text
- View/download PDF
19. Epidural Cystic Spinal Meningioma: A Case Report.
- Author
-
Zhang, Ji, Chen, Zheng-He, Wang, Zi-Feng, Sun, Peng, Jin, Jie-Tian, Zhang, Xiang-Heng, Zhao, Yi-Ying, Wang, Jian, Mou, Yong-Gao, and Chen, Zhong-Ping
- Published
- 2016
- Full Text
- View/download PDF
20. Identification of P4HA1 as a prognostic biomarker for high-grade gliomas.
- Author
-
Hu, Wan-ming, Zhang, Ji, Sun, Shu-xin, Xi, Shao-yan, Chen, Zhi-jie, Jiang, Xiao-bing, Lin, Fu-hua, Chen, Zheng-he, Chen, Yin-sheng, Wang, Jian, Yang, Qun-ying, Guo, Cheng-cheng, Mou, Yong-gao, Chen, Zhong-ping, Zeng, Jing, and Sai, Ke
- Subjects
- *
GLIOMAS , *HYDROXYLASES , *EXTRACELLULAR matrix , *CANCER invasiveness , *GENETIC overexpression , *IMMUNOHISTOCHEMISTRY - Abstract
Background Prolyl 4-Hydroxylase Subunit Alpha 1 (P4HA1) is the active catalytic component of prolyl 4-hydroxylase and plays a crucial role in modulating extracellular matrix hemostasis. P4HA1 has been reported to promote tumor progression by enhancing invasion and angiogenesis. Overexpression of P4HA1 is associated with decreased survival for patients with breast and prostate cancer. However, the prognostic significance of P4HA1 for glioma patients remains undefined. Methods The expression of P4HA1 in 290 gliomas (WHO grade II–IV) and 10 normal brain tissues was examined with TMA-based immunohistochemistry assay. The correlation between P4HA1 expression and clinicopathological parameters as well as the prognosis of glioma patients was investigated. Results Cytoplasmic expression of P4HA1 is high in 37.93% of all glioma cases, with 44.98% in high-grade gliomas and 19.75% in low-grade gliomas respectively. Increased P4HA1 level was correlated with advanced histological grade ( p < 0.01) and old age ( p = 0.01). Upregulation of P4HA1, as well as histological grade, was an independent risk factor for unfavorable prognosis. Subgroup analysis demonstrated that high P4HA1 expression was significantly associated with poor prognosis for high-grade gliomas ( p < 0.01) but not for low-grade gliomas. Conclusions P4HA1 was upregulated in gliomas. High expression of P4HA1 was correlated with the malignancy of gliomas and could serve as a prognostic indicator for patients with high-grade gliomas. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
21. Assessment of ctDNA in CSF may be a more rapid means of assessing surgical outcomes than plasma ctDNA in glioblastoma.
- Author
-
Li, Jue-hui, He, Zhen-qiang, Lin, Fu-hua, Chen, Zheng-he, Yang, Shi-yu, Duan, Hao, Jiang, Xiao-bing, Al-Nahari, Fuad, Zhang, Xiang-heng, Wang, Jiang-huang, Zhang, Guan-hua, Zhang, Zhen-feng, Li, Cong, and Mou, Yong-Gao
- Subjects
- *
CEREBROSPINAL fluid examination , *CEREBROSPINAL fluid , *CIRCULATING tumor DNA ,CENTRAL nervous system tumors - Abstract
We aimed to develop a high-throughput deep DNA sequencing assay of cerebrospinal fluid (CSF) to identify clinically relevant oncogenic mutations that contribute to the development of glioblastoma (GBM) and serve as biomarkers to predict patients' responses to surgery. For this purpose, we recruited five patients diagnosed with highly suspicious GBM according to preoperative magnet resonance imaging. Subsequently, patients were histologically diagnosed with GBM. CSF was obtained through routine lumbar puncture, and plasma from peripheral blood was collected before surgery and 7 days after. Fresh tumor samples were collected using routine surgical procedures. Targeted deep sequencing was used to characterize the genomic landscape and identify mutational profile that differed between pre-surgical and post-surgical samples. Sequence analysis was designed to detect protein-coding exons, exon-intron boundaries, and the untranslated regions of 50 genes associated with cancers of the central nervous system. Circulating tumor DNAs (ctDNAs) were prepared from the CSF and plasma from peripheral blood. For comparison, DNA was isolated from fresh tumor tissues. Non-silent coding variants were detected in CSF and plasma ctDNAs, and the overall minor allele frequency (MAF) of the former corresponded to an earlier disease stage compared with that of plasma when the tumor burden was released (surgical removal). Gene mutation loads of GBMs significantly correlated with overall survival (OS, days) (Pearson correlation = −0.95, P = 0.01). We conclude that CSF ctDNAs better reflected the sequential mutational changes of driver genes compared with those of plasma ctDNAs. Deep sequencing of the CSF of patients with GBM may therefore serve as an alternative clinical assay to improve patients' outcomes. • The comparison of CSF and plasma samples in each single patient with GBM shows that ctDNA in CSF better reflect the sequential change of those tumor drivers than in plasma, implicating a potential value of serial sampling of CSF to monitor key mutations within GBM burden and/or minimal residual tumor. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.